Delayed onset of skin fibrosis after the ingestion of eosinophilia-myalgia syndrome-associated L-tryptophan

Journal of the American Academy of Dermatology

Volumn 35, Issue 2 PART I, 1996, Pages 264-266

  Greenberg, Adam S ^a   Takagi, Hajime ^a   Hill, Robert H ^c   Hasan, Anthony ^a   Murata, Hiroshi ^a   Falanga, Vincent ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PREDNISONE; TRYPTOPHAN;

ADULT; AMINO ACID ANALYSIS; ARTICLE; CASE REPORT; EOSINOPHILIA MYALGIA SYNDROME; FASCIITIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; SKIN FIBROSIS; SYMPTOMATOLOGY; TRYPTOPHAN METABOLISM;

ADULT; EOSINOPHILIA-MYALGIA SYNDROME; FEMALE; FIBROSIS; HAND DERMATOSES; HUMANS; LEG DERMATOSES; SKIN; TRYPTOPHAN;

EID: 0029743896     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0190-9622(96)90347-3     Document Type: Article

References (13)

1. Silver RM, Heyes M, Maize JC, et al. Scleroderma, fasciitis, and eosinophilia associated with ingestion of tryptophan. N Engl J Med 1990;322:874-81.
2. Varga J, Jimenez SA. Chemical exposure-induced cutaneous fibrosis: lessons from "experiments of nature." Arch Dermatol 1994;130:97-100.
3. Blauvelt A, Falanga V. Idiopathic and L-tryptophan-associated eosinophilic fasciitis before and after L-tryptophan contamination. Arch Dermatol 1991;27:1159-66.
4. Hill RH Jr, Caudill SP, Philen RM, et al. Contaminants in L-tryptophan associated with eosinophilia myalgia syndrome. Arch Environ Contam Toxicol 1993;25:134-42.
5. Belongia EA, Hedberg CW, Gleich GJ, et al. An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N Engl J Med 1990; 323:357-65.
6. Yamaoka KA, Miyasaka N, Inou G, et al. 1,1-ethylidenebis(tryptophan) (peak E) induces functional activation of human eosinophils and interleukin 5 production from T lymphocytes: association of eosinophilia-myalgia syndrome with a L-tryptophan contaminant. J Crin Immunol 1994;14:50-60.
7. Crofford LJ, Rader JI, Dalakas MC, et al. L-Tryptophan implicated in human eosinophilia-myalgia syndrome causes fasciitis and perimyositis in the Lewis rat. J Clin Invest 1990;86:1757-63.
8. Silver RM, Ludwicka A, Hampton M, et al. A murine model of the eosinophilia-myalgia syndrome induced by 1,1'-ethylidenebis (L-tryptophan). J Clin Invest 1994;93:1473-80.
9. Slutsker L, Hoesly PC, Miller L, et al. Eosinophilia-myalgia syndrome associated with exposure to tryptophan from a single manufacturer. JAMA 1990;264:213-7.
10. Love LA, Rader JI, Crofford LJ, et al. Pathological and immunological effects of ingesting L-tryptophan and 1,1-ethylidenebis(L-tryptophan) in Lewis rats. J Clin Invest 1993;91:804-11.
11. Takagi H, Ochoa S, Zhou L, et al. Enhanced collagen synthesis and transcription by peak E, a contaminant of L-tryptophan preparations associated with the EMS epidemic. J Clin Invest 1995;96:2120-5.
12. Falanga V, Medsger TA. The frequency, levels, and significance of blood eosinophilia in systemic sclerosis, localized scleroderma, and eosinophilic fasciitis. J Am Acad Dermatol 1987;17:648-56.
13. de Oliveira JS, Auerbach SB, Sullivan KM, et al. Fatal eosinophilia myalgia syndrome in a marrow transplant patient attributed to total parenteral nutrition with a solution containing tryptophan. Bone Marrow Transplant 1993;11: 163-7.